公开(公告)号：US20220007704A1

公开(公告)日：2022-01-13

申请号：US17486328

申请日：2021-09-27

申请人： ABBOTT LABORATORIES

发明人： TAPAS DAS ,  MUSTAFA VURMA ,  CHRON-SI LAI ,  PAUL JOHNS

IPC分类号： A23L33/00 ,  A61K38/01 ,  A23L33/12 ,  A23L33/19 ,  A23L33/18 ,  A23L33/115 ,  A61K45/06 ,  A23L29/00 ,  A61P25/28

摘要： Disclosed embodiments provide nutritional compositions and methods of enhancing maturation of an infant's brain. The methods include the step of administering to the infant a nutritional composition comprising a protein with a degree of hydrolysis of 10% to 75% in combination with at least one of a monoglyceride, a free fatty acid, a salt of a free fatty acid, a phospholipid, and cholesterol.

公开(公告)号：US20190000913A1

公开(公告)日：2019-01-03

申请号：US16066557

申请日：2016-12-27

申请人： ABBOTT LABORATORIES

发明人： TAPAS DAS ,  MUSTAFA VURMA ,  CHRON-SI LAI ,  PAUL JOHNS

IPC分类号： A61K38/01 ,  A61P1/00 ,  A23L33/18 ,  A23L33/00 ,  A23L33/125

摘要： Disclosed embodiments provide a method of enhancing maturation of a lung, brain, or both, in an infant. The method includes the step of administering to the infant a nutritional composition comprising a protein with a degree of hydrolysis of 10% to 75%. Also disclosed are methods for reducing the incidence of necrotizing enterocolitis in an individual. In addition, the disclosed embodiments provide a method for the prevention, delay of progression, or the treatment of a circulatory disorder characterized by inadequate blood flow to the brain or lung.

公开(公告)号：US20220346429A1

公开(公告)日：2022-11-03

申请号：US17853515

申请日：2022-06-29

申请人： ABBOTT LABORATORIES

发明人： TAPAS DAS ,  MUSTAFA VURMA ,  CHRON-SI LAI ,  PAUL JOHNS

IPC分类号： A23L33/00 ,  A61K38/01 ,  A23L33/12 ,  A23L33/19 ,  A23L33/18 ,  A23L33/115 ,  A61K45/06 ,  A23L29/00 ,  A61P25/28

摘要： Disclosed embodiments provide nutritional compositions and methods of enhancing maturation of an infant's brain. The methods include the step of administering to the infant a nutritional composition comprising a protein with a degree of hydrolysis of 10% to 75% in combination with at least one of a monoglyceride, a free fatty acid, a salt of a free fatty acid, a phospholipid, and cholesterol.

公开(公告)号：US20170238583A1

公开(公告)日：2017-08-24

申请号：US15588950

申请日：2017-05-08

申请人： ABBOTT LABORATORIES

发明人： GUARAV PATEL ,  PAUL JOHNS ,  NORMANELLA DEWILLE ,  SUZETTE PEREIRA

IPC分类号： A23L2/52 ,  A23L2/66 ,  A23L2/46

CPC分类号： A23L2/52 ,  A23L2/46 ,  A23L2/66 ,  A23L33/105 ,  A23L33/17 ,  A23L33/40 ,  A23V2002/00 ,  A23V2200/00 ,  A61K36/82 ,  A23V2250/214 ,  A23V2250/5424 ,  A23V2250/54244

摘要： Disclosed herein are shelf-stable, clear liquid nutritional compositions having a pH ranging from 2.5 to 4.6 and comprising water; at least one source of EGCg in an amount sufficient to provide 200-1700 mg/L of EGCg; and at least one source of protein in an amount sufficient to provide 25-45 g/L of total protein. The shelf-stable, clear liquid nutritional compositions lose no more than 20% by weight solids of the EGCg content present in the initial formulation of the compositions to epimerization, degradation, or both epimerization and degradation during heat sterilization. In certain embodiments, the loss of EGCg is exhibited by the amount of epimerization product GCg present in the shelf-stable, clear liquid nutritional composition following heat sterilization. Methods for preparing the shelf-stable, clear liquid nutritional compositions are also disclosed herein.

公开(公告)号：US20190014807A1

公开(公告)日：2019-01-17

申请号：US16066585

申请日：2016-12-27

申请人： ABBOTT LABORATORIES

发明人： TAPAS DAS ,  MUSTAFA VURMA ,  CHRON-SI LAI ,  PAUL JOHNS

IPC分类号： A23L33/00 ,  A23L33/12 ,  A23L33/18 ,  A23L33/19 ,  A23L29/00 ,  A61K38/01 ,  A61P25/28

摘要： Disclosed embodiments provide nutritional compositions and methods of enhancing maturation of an infant's brain. The methods include the step of administering to the infant a nutritional composition comprising a protein with a degree of hydrolysis of 10% to 75% in combination with at least one of a monoglyceride, a free fatty acid, a salt of a free fatty acid, a phospholipid, and cholesterol.

公开(公告)号：US20170202864A1

公开(公告)日：2017-07-20

申请号：US15327698

申请日：2015-07-21

申请人： ABBOTT LABORATORIES

发明人： CHRISTINE GALLARDO ,  GARY GORDON ,  PAUL JOHNS ,  GARY KATZ ,  MARK ENGLE

IPC分类号： A61K31/702 ,  A23L33/00 ,  A61K9/00 ,  A23L29/30 ,  A61K35/745 ,  A61K9/14

CPC分类号： A61K31/702 ,  A23L5/00 ,  A23L21/00 ,  A23L29/30 ,  A23L33/00 ,  A23L33/10 ,  A23L33/125 ,  A23L33/40 ,  A23V2002/00 ,  A61K9/0053 ,  A61K9/14 ,  A61K35/745 ,  A61K2300/00

摘要： Disclosed herein are nutrient delivery systems comprising a pod and a nutritional powder comprising a human milk oligosaccharide or a precursor thereof.

公开(公告)号：US20170086481A1

公开(公告)日：2017-03-30

申请号：US15315987

申请日：2015-06-03

申请人： ABBOTT LABORATORIES

发明人： PAUL JOHNS ,  MUSTAFA VURMA ,  STEPHEN DEMICHELE ,  GARY KATZ

IPC分类号： A23L2/52 ,  A23L33/15 ,  A23L33/19

CPC分类号： A23L2/52 ,  A23C2230/15 ,  A23L27/80 ,  A23L33/105 ,  A23L33/15 ,  A23L33/19 ,  A23V2002/00 ,  A23V2250/192 ,  A23V2250/54246

摘要： Disclosed embodiments provide methods and compositions for improving the metabolic health of consumers. Bovine beta-casein, a major component of milk from cattle, has many genetic variants. Certain genetic variants, A1 in particular, have been associated with type 1 diabetes. The disclosed methods and compositions include reduced amounts of genetic variants of beta-casein that have been associated with diabetes. In some embodiments, the compositions display improved emulsions due to the solubility and hydrophobicity of the genetic variants of beta-casein used therein.

公开(公告)号：US20160317600A1

公开(公告)日：2016-11-03

申请号：US15105059

申请日：2014-12-18

申请人： ABBOTT LABORATORIES

发明人： PAUL JOHNS ,  CYNTHIA NEAL ,  JOHN MCEWEN ,  RONALD MCKENNA

IPC分类号： A61K38/01 ,  A61K33/34 ,  A61K31/202 ,  A61K9/00 ,  A23L33/12 ,  A23L33/115 ,  A23L33/00 ,  A23L33/15 ,  A23L33/125 ,  A23L33/18 ,  A23L33/21 ,  A61K31/375 ,  A23L33/19

CPC分类号： A61K38/018 ,  A23L33/115 ,  A23L33/12 ,  A23L33/125 ,  A23L33/15 ,  A23L33/16 ,  A23L33/17 ,  A23L33/18 ,  A23L33/19 ,  A23L33/21 ,  A23L33/30 ,  A23L33/40 ,  A23V2002/00 ,  A23V2200/00 ,  A61K9/0095 ,  A61K31/202 ,  A61K31/375 ,  A61K33/34 ,  A61K45/06 ,  A61K2300/00 ,  A23V2250/0612 ,  A23V2250/0644 ,  A23V2250/5036 ,  A23V2250/702 ,  A23V2250/71 ,  A23V2250/712 ,  A23V2250/714

摘要： Liquid nutritional compositions include specific combinations of protein, carbohydrate, and fat for the nutritional support of individuals with particular needs, such as individual suffering from obesity. The compositions comprise a source of at least one omega-6 fatty acid and a source of at least one omega-3 fatty acid with a ratio of omega-6 to omega-3 of 1:5 to 1:1. In a preferred form the compositions comprise at least one hydrolysed dairy protein selected from hydrolysed whey protein and hydrolysed casein protein or mixtures thereof. Methods of administering such nutritional compositions are also provided. Further liquid nutritional compositions comprise protein in an amount of 1-12% by weight of the liquid nutritional composition, vitamin C and copper, wherein the protein comprises a mixture of whey protein and casein with a majority of the whey protein having a degree of hydrolysis greater than 20%. Methods for improving vitamin C stability in these liquid nutritional compositions are also provided.

摘要翻译： 液体营养组合物包括蛋白质，碳水化合物和脂肪的特定组合，用于具有特殊需要的个体的营养支持，例如患有肥胖的个体。 组合物包含至少一种ω-6脂肪酸的源和至少一种ω-6至ω-3的比例为1:5至1:1的ω-3脂肪酸的来源。 在优选形式中，组合物包含至少一种选自水解乳清蛋白和水解酪蛋白的水解乳蛋白或其混合物。 还提供了施用这种营养组合物的方法。 另外的液体营养组合物包含量为液体营养组合物，维生素C和铜的1-12重量％的蛋白质，其中蛋白质包含乳清蛋白和酪蛋白与大部分具有水解度的乳清蛋白质的混合物 大于20％。 还提供了用于改善这些液体营养组合物中维生素C稳定性的方法。